NEW YORK – Twist Bioscience said on Tuesday that it is collaborating with Artisan Development Labs (Artisan Bio) to discover novel antibodies against five undisclosed targets.
Under the terms of the collaboration, Twist will apply its proprietary Library of Libraries to discover novel antibodies directed against Artisan Bio's immunotherapy targets. Artisan will leverage its Immune Cell Engineering Foundry and STAR Guides to develop custom cell therapeutics. Twist will receive upfront technology access and project fees for each program; success-based clinical, regulatory, and commercial milestones; and royalties on product sales.
The deal includes an option for additional targets. Other details were not disclosed.
"Artisan has a unique approach that combines a deep understanding of this gene-editing technology with advanced AI analysis," Twist cofounder and CEO Emily Leproust said in a statement. "Our collaboration with Artisan will leverage our innovative antibody discovery capabilities to help translate this cutting-edge approach into novel cell therapies."
Artisan Bio has operations in Denver; Copenhagen, Denmark; and Toronto. According to its website, it has received investment from XSeed Capital, Northpond Ventures, and Takeda Ventures.